Labcorp Holdings Inc. (NYSE:LH) Plans Quarterly Dividend of $0.72

Key Points

• Labcorp declared a quarterly dividend of $0.72 per share, payable June 11 to holders of record on May 29, which annualizes to $2.88 and yields about 1.1%.
• Dividend coverage is strong — the company has a payout ratio of roughly 16.4% and analysts expect about $17.5 EPS next year (FY2026 guidance $17.55–$18.25), indicating the dividend is well supported by earnings.
• Market and analyst view — shares recently traded near $273.68 (market cap ≈ $22.6B, PE ≈ 26.2), with a consensus "Moderate Buy" and an average price target of $307.70 from analysts.

Labcorp Holdings Inc. (NYSE:LH - Get Free Report) declared a quarterly dividend on Thursday, April 9th. Investors of record on Friday, May 29th will be given a dividend of 0.72 per share by the medical research company on Thursday, June 11th. This represents a c) annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th.

Labcorp has a dividend payout ratio of 16.4% meaning its dividend is sufficiently covered by earnings. Research analysts expect Labcorp to earn $17.54 per share next year, which means the company should continue to be able to cover its $2.88 annual dividend with an expected future payout ratio of 16.4%.

Labcorp Stock Performance

Shares of NYSE LH traded down $1.04 during mid-day trading on Thursday, hitting $273.68. The stock had a trading volume of 451,144 shares, compared to its average volume of 683,211. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The company has a 50 day moving average of $274.52 and a two-hundred day moving average of $268.89. Labcorp has a twelve month low of $209.38 and a twelve month high of $293.72. The firm has a market cap of $22.55 billion, a PE ratio of 26.16, a PEG ratio of 1.87 and a beta of 1.02.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.12. The company had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The firm's revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Research analysts predict that Labcorp will post 16.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LH has been the topic of several analyst reports. Piper Sandler increased their price target on Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 24th. Wall Street Zen downgraded Labcorp from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Robert W. Baird increased their price target on Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. Morgan Stanley reaffirmed an "overweight" rating on shares of Labcorp in a research report on Tuesday, February 17th. Finally, Weiss Ratings raised Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, February 10th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $307.70.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.